Tuesday - November 26, 2024
University of Houston: A New Weapon Against the Super Tough C Diff Bacteria
December 20, 2023
HOUSTON, Texas, Dec. 20 (TNSres) -- The University of Houston issued the following news release:

* * *

Phase 1 Trial Shows New RX Fights C Diff and Spares Healthy Microbiota

* * *

In a phase-one human clinical trial, a University of Houston pharmacist researcher has demonstrated that a newer generation tetracycline antibiotic, called Omadacycline, may be a promising tool in combating the resilient bacteria Clostridioides difficile (C diff), whi . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products